Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 144 of 5804
-
New drug combo aims to tackle stubborn hepatitis d
Disease control OngoingThis is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Cholesterol-Lowering drug may boost lung cancer immunotherapy
Disease control Recruiting nowThis is a single arm, multi-center clinical trial. The goal of this clinical trial is to evaluate the efficacy, safety and biomarkers of Tafolecimab combined with Sintilimab and Chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Gene therapy builds Cancer-Killing cells inside you – no lab needed
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Phase: PHASE1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New shorter chemo combo shows promise for hodgkin lymphoma
Disease control Recruiting nowThe purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective t…
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill combo aims to protect vulnerable from severe COVID
Disease control Recruiting nowThis is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severel…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug cocktail aims to tackle recurrent head and neck cancer
Disease control Recruiting nowThe study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Radiation-Immuno combo targets tough liver cancer clot
Disease control Recruiting nowPatients with PVTT involvement is a significant healthcare burden as they are present in up to 40% of patients with HCC at diagnosis. These patients exhibit a poorer prognosis compared to patients without PVTT, as a result they were often excluded from existing pivotal clinical t…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for tough lung cancers: ivonescimab combo enters phase 3 trial
Disease control Recruiting nowThis is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based t…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a higher aspirin dose stop preterm births? large trial launches
Prevention Recruiting nowThis is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 1…
Phase: PHASE3 • Sponsor: The George Washington University Biostatistics Center • Aim: Prevention
Last updated Jun 27, 2026 12:05 UTC
-
New radioactive cocktail aims to shrink tough prostate tumors
Disease control Recruiting nowThe purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investiga…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo aims to stop ovarian Cancer's return
Disease control Recruiting nowThis is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
Phase: PHASE2, PHASE3 • Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
Disease control Recruiting nowThis research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma. The n…
Phase: PHASE1 • Sponsor: Steven DuBois, MD • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a stomach tuck reverse fatty liver?
Disease control Recruiting nowMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other…
Phase: NA • Sponsor: Pichamol Jirapinyo, MD, MPH • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to outsmart resistant breast cancer
Disease control Recruiting nowThis is an open-label, single-center, exploratory, Phase Ib/II clinical trial evaluating the safety and efficacy of entinostat combined with pyrotinib and endocrine therapy in patients with advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-posi…
Phase: PHASE1, PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New cream could ease painful skin bumps for HS patients
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could this drug help patients with Hard-to-Treat breast cancer?
Disease control Recruiting nowThe purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a common heart drug boost ovarian cancer treatment?
Disease control Recruiting nowOvarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors. Cytoreductive Surgery (CRS) combined with chemotherapy is th…
Phase: PHASE2 • Sponsor: Bai-Rong Xia • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New obesity drug shows promise in major japanese trial
Disease control OngoingThe primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Could a single daily pill slash heart disease risks?
Disease control Recruiting nowThe EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a max…
Phase: PHASE3 • Sponsor: Hospital do Coracao • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could a diabetes drug protect obese Teens' hearts?
Disease control Recruiting nowThe goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index …
Sponsor: John Bauer • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC